Global Plasmid DNA Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Plasmid DNA Contract Manufacturing Market is presumed to reach the market size of nearly USD 1581.61 MN by 2030 from USD 313.53 MN in 2022 with a CAGR of 22.42% under the study period 2023 - 2030.

Plasmid DNA contract manufacturing is the process of outsourcing the production of plasmid DNA to a third-party contract manufacturer. Plasmid DNA is a type of DNA used in various applications, including gene therapy, vaccine development, and research. It is a circular piece of DNA that is separate from the main chromosome and can replicate independently in a cell. Plasmid DNA contract manufacturing involves the production of plasmid DNA on a large scale, typically in the tens to hundreds of grams.

Market Dynamics:

The growing demand for gene therapy increases the need for plasmid DNA, which is driving the market for plasmid DNA contract manufacturing. Moreover, plasmid DNA is often used to develop personalized medicine, as it can be customized to specific patient needs. This is driving the demand for plasmid DNA contract manufacturing. Furthermore, technological advances in the production technology for plasmid DNA have made it more efficient and cost-effective, which has contributed to the market's growth. In addition, the rising demand for research drives the plasmid DNA contract manufacturing market growth. However, the regulatory requirements may impede the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of plasmid dna contract manufacturing. The growth and trends of plasmid dna contract manufacturing industry provide a holistic approach to this study.

Market Segmentation:

This section of the plasmid dna contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Cell & Gene Therapy
Immunotherapy
Others

By Therapeutic Area

Cancer
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Others

By End-User

Pharmaceutical And Biotechnology Companies
Research Institutes

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Plasmid DNA Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the plasmid dna contract manufacturing market include Charles River Laboratories, VGXI Inc., PlasmidFactory GmbH & Co. KG, Boehringer Ingelheim, BioCina, TriLink Biotechnologies, Aster PTE. LTD, Thermo Fisher Scientific, Inc., VIVE biotech, Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110153

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PLASMID DNA CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Therapeutic Area
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Cell & Gene Therapy Historic and Forecast Sales by Regions
6.5 Immunotherapy Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY THERAPEUTIC AREA

7.1 Overview by Therapeutic Area
7.2 Historical and Forecast Data
7.3 Analysis by Therapeutic Area
7.4 Cancer Historic and Forecast Sales by Regions
7.5 Infectious Diseases Historic and Forecast Sales by Regions
7.6 Autoimmune Diseases Historic and Forecast Sales by Regions
7.7 Cardiovascular Diseases Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Pharmaceutical And Biotechnology Companies Historic and Forecast Sales by Regions
8.5 Research Institutes Historic and Forecast Sales by Regions

9 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PLASMID DNA CONTRACT MANUFACTURING COMPANIES

10.1. Plasmid Dna Contract Manufacturing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF PLASMID DNA CONTRACT MANUFACTURING INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Charles River Laboratories
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. VGXI Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. PlasmidFactory GmbH & Co. KG
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Boehringer Ingelheim
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. BioCina
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. TriLink Biotechnologies
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Aster PTE. LTD
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Thermo Fisher Scientific Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. VIVE biotech
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Lonza
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies